NCT02169791View on ClinicalTrials.gov

Nonmyeloablative Haploidentical Transplant Followed by MLN9708

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 15, 2014

Primary Completion Date

July 28, 2020

Study Completion Date

July 28, 2020

Conditions
Acute LeukemiaChronic LeukemiaMyelodysplastic SyndromeLymphomasMultiple Myeloma
Interventions
DRUG

MLN9708

MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.

Trial Locations (1)

30342

Northside Hospital, Atlanta

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Northside Hospital, Inc.

OTHER

NCT02169791 - Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | Biotech Hunter | Biotech Hunter